Mukka Proteins IPO: GMP, Subscription Status, and Review
2 min read
The initial public offering (IPO) of Mukka Proteins Limited has garnered significant attention in the primary market. With the bidding process set to end today, potential investors are keen to review the grey market premium (GMP) and subscription status before making their investment decisions. In this article, we will provide an overview of the current GMP, subscription status, and offer some insights for investors to consider.
Mukka Proteins IPO GMP today stands at ₹30, an increase of ₹2 from the previous day’s GMP of ₹28. This rise can be attributed to the strong response from primary market investors and the overall bullish trend in the Indian stock market. Market experts believe that positive global market sentiments may further fuel the sentiment surrounding the Mukka Proteins IPO in the upcoming sessions.
The subscription for the Mukka Proteins IPO opened on February 29, 2024, and will close today, on March 4, 2024. Investors have just one day left to apply for the public issue. The company has already raised ₹67.20 crore from anchor investors and aims to raise a total of ₹224 crore through the issuance of fresh shares only. The price band for the IPO has been set at ₹26 to ₹28 per equity share.
As per the latest subscription status, the book build issue has been subscribed 6.97 times in the first two days of bidding. By 10:54 AM on day 3 of the bidding, the IPO had been subscribed 23.25 times overall. The retail portion of the book build issue was subscribed 19.68 times, while the non-institutional investors portion was subscribed 59.80 times. The qualified institutional buyer segment was subscribed 2.07 times.
It is important to note that the grey market continues to remain highly bullish on the Mukka Proteins IPO. The current GMP of ₹30 indicates the positive sentiment among grey market participants. However, it is essential for investors to exercise caution and conduct thorough research before making any investment decisions.
Investors should consider various factors before deciding whether to apply for the Mukka Proteins IPO. It is advisable to consult with certified experts and analyze the company’s financials, business model, and growth prospects. Additionally, understanding the risks associated with investing in the stock market is crucial.S
In conclusion, the Mukka Proteins IPO has generated significant interest in the market. With the bidding process ending today, investors are closely monitoring the GMP and subscription status. It is important for investors to carefully evaluate the company and seek professional advice before making any investment decisions.
Disclaimer: Please note that the views and recommendations mentioned in this article are those of individual analysts, experts, and broking companies, We always advise investors to seek advice from certified experts before making any investment decisions.
